CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor is a research paper published in Immunity (2022). On theSindex it has a DataRank of 0. It has been cited 350 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R00 CA197804
NCATS NIH HHS
Grant: UL1 TR002378
NCI NIH HHS
Grant: U01 CA113913
NCI NIH HHS
Grant: L30 CA231673
NIH HHS
Grant: P51 OD011132
NIH HHS
Grant: S10 OD026799
National Institutes of Health
Grant: 5U01CA113913-10
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
National Institutes of Health
Grant: 5UL1TR002378-09
Georgia Clinical & Translational Science Alliance (Georgia CTSA)
National Institutes of Health
Grant: 4R00CA197804-03
Epigenetic Mechanisms Controlling T-cell Exhaustion in Prostate Cancer
National Institutes of Health
Grant: 1S10OD026799-01
Illumina NovaSeq 6000 High Throughput DNA Sequencer for Emory University
National Institutes of Health
Grant: 3P51OD011132-64S2
Renovation to expand and enhance NHP housing for HIV/AIDS research at the Emory NPRC
FWCI
21.62
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of T1 and T2 mapping for identifying malignant lymph nodes in head and neck squamous cell carcinoma
Additional file 1 of T1 and T2 mapping for identifying malignant lymph nodes in head and neck squamous cell carcinoma
Additional file 2 of A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Additional file 2 of A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Additional file 1 of A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Additional file 1 of A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune